Membrane Vesicles from Lactobacillus Acidophilus Reduce Intestinal Inflammation and Increase 5-HT in the Substantia

Khadijeh Sheikh1, Javad Arasteh1, Maryam Tajabadi Ebrahimi1

  • 1Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran.

PubMed
Abstract

Insights

Membrane vesicles (MVs) from Lactobacillus acidophilus show potential in treating Parkinson's disease by reducing inflammation and improving neurotransmitter levels. This probiotic-derived therapy may offer a novel approach to managing neurological disorders via the gut-brain axis.

Area of Science:

  • Neuroscience
  • Microbiology
  • Gastroenterology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder with complex pathophysiology.
  • Intestinal inflammation and altered neurotransmitter levels are implicated in PD progression.
  • Probiotic-derived membrane vesicles (MVs) are emerging as potential therapeutic agents.

Purpose of the Study:

  • To investigate the therapeutic potential of Lactobacillus acidophilus MVs in a rat model of PD.
  • To assess the effect of MVs on intestinal inflammation and key neurotransmitters in the substantia nigra.
  • To explore the role of MVs in modulating the gut-brain axis in PD.

Main Methods:

  • A 6-hydroxydopamine (6-OHDA) rat model of PD was established.
  • Rats received MVs from L. acidophilus via oral gavage.
  • Brain and intestinal tissues were analyzed for molecular and cellular changes.

Main Results:

  • 6-OHDA induced significant motor deficits and altered neurotransmitter expression (decreased 5-HT, increased GABA) in the substantia nigra.
  • MVs mitigated these neurological changes in 6-OHDA-treated rats.
  • Intestinal tissue showed increased TLR-4 and α-synuclein gene expression in the PD model, which was modulated by MV treatment.

Conclusions:

  • L. acidophilus MVs demonstrate potential in reducing intestinal inflammation and neurological damage in PD.
  • MVs may restore 5-HT neurotransmitter levels, suggesting a therapeutic role in Parkinson's disease.
  • The findings highlight the therapeutic potential of MVs in modulating the gut-brain axis for PD management.